Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
J Natl Compr Canc Netw. 2024 Apr;22(3):175-204. doi: 10.6004/jnccn.2024.0018.ABSTRACTChronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based ...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 16, 2024 Category: Cancer & Oncology Authors: William G Wierda Jennifer Brown Jeremy S Abramson Farrukh Awan Syed F Bilgrami Greg Bociek Danielle Brander Matthew Cortese Larry Cripe Randall S Davis Herbert Eradat Bita Fakhri Christopher D Fletcher Sameh Gaballa Muhammad Saad Hamid Brian Hill Paul Kae Source Type: research
Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
CONCLUSION: Our data indicate that if aggressive lymphoid neoplasms develop during the course of treatment in patients with MPNs, it is acceptable to prioritize chemotherapy for lymphoma.PMID:38626148 | DOI:10.1080/16078454.2024.2340149 (Source: Hematology)
Source: Hematology - April 16, 2024 Category: Hematology Authors: Yoko Edahiro Tomonori Ochiai Yoshinori Hashimoto Michiko Ichii Takeshi Okatani Hiromi Omura Kei Nakajima Makoto Sasaki Jun Ando Tomoiku Takaku Michiaki Koike Koh Izumiyama Junji Hiraga Tomofumi Yano Kensuke Usuki Eiichi Ohtsuka Kenji Yokoyama Tatsuo Oyake Source Type: research
Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs
CONCLUSION: In this case, the first ALK resistance mutation detected after progression on first line TKI, the I1171N, is a common resistance mutation after alectinib and confers sensitivity to brigatinib, that the patient received afterwards with a long-term disease stability. The second ALK resistance mutation detected after a chemotherapy interval, the G1202R, is the most common resistance mutation after second generation ALK TKIs and has been associated with sensitivity to third generation TKIs, such as lorlatinib. This case of a patient with EML4-ALK-rearranged NSCLC shows that sequential treatment with next-generation...
Source: Tumori - April 16, 2024 Category: Cancer & Oncology Authors: Rita Leporati Daniela Miliziano Teresa Beninato Laura Mazzeo Sara Manglaviti Marta Brambilla Mario Occhipinti Arsela Prelaj Claudia Proto Giuseppe Lo Russo Source Type: research
BCL2A1 neoepitopes-elicited cytotoxic T lymphocytes are a promising individualized immunotherapy of pancreatic cancer
J Leukoc Biol. 2024 Apr 16:qiae092. doi: 10.1093/jleuko/qiae092. Online ahead of print.ABSTRACTConventional treatments have shown a limited efficacy for pancreatic cancer, and immunotherapy is an emerging option for treatment of this highly fatal malignancy. Neoantigen is critical to improving the efficacy of tumor-specific immunotherapy. The cancer and peripheral blood specimens from human leukocyte antigen (HLA)-A0201 positive pancreatic cancer patient were subjected to next-generation sequencing and bioinformatics analyses were performed to screen high-affinity and highly stable neoepitopes. The activation of cytotoxic ...
Source: Journal of Leukocyte Biology - April 16, 2024 Category: Hematology Authors: Shengzhe Lin Jingwen Hong Suxin Wu Chenlu Zhu Fang Liu Wansong Lin Xinran Cai Yunbin Ye Yanling Chen Source Type: research
Population pharmacokinetics and exposure –response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study
AbstractPolatuzumab vedotin is a CD79b-directed antibody –drug conjugate that targets B cells and delivers the cytotoxic payload monomethyl auristatin E (MMAE). The phase III POLARIX study (NCT03274492) evaluated polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) as first-line treatment of diffuse la rge B-cell lymphoma (DLBCL). To examine dosing decisions for this regimen, population pharmacokinetic (popPK) analysis, using a previously developed popPK model, and exposure–response (ER) analysis, were performed. The popPK analysis showed no clinically meaningful rela...
Source: CPT: Pharmacometrics and Systems Pharmacology - April 16, 2024 Category: Drugs & Pharmacology Authors: Rong Deng,
Leonid Gibiansky,
Tong Lu,
Christopher R. Flowers,
Laurie H. Sehn,
Qi Liu,
Priya Agarwal,
Michael Z. Liao,
Randall Dere,
Calvin Lee,
Gabriel Man,
Jamie Hirata,
Chunze Li,
Dale Miles Tags: ARTICLE Source Type: research
MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases
MNDA (myeloid nuclear differentiation antigen) has been considered as a potential diagnostic marker for marginal zone lymphoma (MZL), but its utility in distinguishing MZL from other B-cell non-Hodgkin lymphom... (Source: Diagnostic Pathology)
Source: Diagnostic Pathology - April 16, 2024 Category: Pathology Authors: Li-Fen Zhang, Yan Zhang, Rou-Hong Shui, Hong-Fen Lu, Wen-Hua Jiang, Xu Cai, Xiao-Qiu Li and Bao-Hua Yu Tags: Research Source Type: research
Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma in the United States
The results of a recent single-arm trial (ZUMA-5) of axicabtagene ciloleucel (axi-cel) for relapsed/refractory (r/r) FL demonstrated high rates of durable response and tolerable toxicity among treated patients. To quantify the value of axi-cel compared to standard of care (SOC) to manage r/r FL patients who have had at least two prior lines of systemic therapy (3L+), a cost-effectiveness model was developed from a US third-party payer perspective. (Source: Value in Health)
Source: Value in Health - April 16, 2024 Category: International Medicine & Public Health Authors: Olalekan O. Oluwole, Markqayne D. Ray, Katherine L. Rosettie, Graeme Ball, Jorge Jacob, S. Pinar Bilir, Anik R. Patel, Caron A. Jacobson Source Type: research
Contemporary Challenges in Polycythemia Vera Management from the Perspective of Patients and Physicians
Although polycythemia vera (PV) is a chronic and incurable disease, effective management can allow most patients to maintain functional lives with near-normal life expectancy. However, there remain several inter-related factors that contribute to many ongoing challenges associated with the management of PV, which this review aims to explore. First, as a disease hallmarked by constitutive activation of the JAK/STAT pathway, PV is often accompanied by inflammatory symptoms that negatively impact quality of life. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 16, 2024 Category: Hematology Authors: Andrew T. Kuykendall, Jennifer T. Fine, Marina Kremyanskaya Source Type: research
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece
CONCLUSION: In this real-world Len-exposed cohort, Len-refractory patients receiving 1L Len experienced poorer survival outcomes than non-Len-refractory patients, highlighting the unmet need in this patient population which has driven the development of novel therapies.PMID:38616479 | DOI:10.1016/j.clml.2024.03.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 15, 2024 Category: Cancer & Oncology Authors: Efstathios Kastritis Ioannis Ntanasis-Stathopoulos Foteini Theodorakakou Magdalini Migkou Maria Roussou Panagiotis Malandrakis Nikolaos Kanellias Evangelos Eleutherakis-Papaiakovou Despina Fotiou Vassiliki Spiliopoulou Maria Gavriatopoulou Sachin Patel Is Source Type: research
Pulmonary Manifestations of Sj ögren's Disease
Semin Respir Crit Care Med. 2024 Apr 15. doi: 10.1055/s-0044-1785675. Online ahead of print.ABSTRACTSjögren's disease (SjD) is a chronic, progressive autoimmune condition of exocrine and extraglandular tissues. It can present with isolated disease characterized by lymphocytic infiltration of salivary or lacrimal glands, but in approximately one-third of the patients, lymphocytic infiltration extends beyond exocrine glands to involve extraglandular organs such as the lungs. Pulmonary complications have been reported to occur between 9 and 27% of patients with SjD across studies. Respiratory manifestations occur on a spectr...
Source: Respiratory Care - April 15, 2024 Category: Respiratory Medicine Authors: Louise Byrne Cormac McCarthy Aurelie Fabre Nishant Gupta Source Type: research
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece
CONCLUSION: In this real-world Len-exposed cohort, Len-refractory patients receiving 1L Len experienced poorer survival outcomes than non-Len-refractory patients, highlighting the unmet need in this patient population which has driven the development of novel therapies.PMID:38616479 | DOI:10.1016/j.clml.2024.03.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - April 15, 2024 Category: Cancer & Oncology Authors: Efstathios Kastritis Ioannis Ntanasis-Stathopoulos Foteini Theodorakakou Magdalini Migkou Maria Roussou Panagiotis Malandrakis Nikolaos Kanellias Evangelos Eleutherakis-Papaiakovou Despina Fotiou Vassiliki Spiliopoulou Maria Gavriatopoulou Sachin Patel Is Source Type: research
Mechanism of resveratrol in protecting ovary in poor ovarian response mice by regulating Hippo signaling pathway
In conclusion, Res effectively inhibits ovarian cell apoptosis in mice and improves ovarian responsiveness. Its mechanism may be related to the regulation of key molecules in the Hippo pathway.PMID:38621878 | DOI:10.19540/j.cnki.cjcmm.20230915.401 (Source: Cell Research)
Source: Cell Research - April 15, 2024 Category: Cytology Authors: Jian-Heng Hao Bo-Ya Chang Jia Ren Hai-Jun Wang Lai-Xi Ji Source Type: research
Application and progress of CRISPR/Cas9 gene editing in B-cell lymphoma: a narrative review
CONCLUSIONS: CRISPR/Cas9 gene editing has great promise in the treatment of B-cell lymphoma. This article reviews some genes, signaling pathways, and cytokines related to the progression and prognosis of B-cell lymphoma to provide a strong theoretical basis.PMID:38617522 | PMC:PMC11009809 | DOI:10.21037/tcr-23-1146 (Source: Cell Research)
Source: Cell Research - April 15, 2024 Category: Cytology Authors: Ying Jin Haiyi Wu Jianzhao Liu William C Cho Guoqi Song Source Type: research
Outcome in patients with HIV-associated Hodgkin lymphoma treated with chemotherapy using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the combination antiretroviral therapy (cART) era: results of a multicenter study from China
Little is known about the outcome for HIV-associated Hodgkin lymphoma (HIV-HL) as this is less common than HIV-negative lymphoma. Therefore, we performed a multi-center study to analyze the clinical characteri... (Source: Infectious Agents and Cancer)
Source: Infectious Agents and Cancer - April 15, 2024 Category: Cancer & Oncology Authors: Lirong Xiao, Chaoyu Wang, Sai Ma, Yifan Wang, Liping Guan, Juyi Wu, Wei Zhang, Yao Liu and Yan Wu Tags: Research Source Type: research
Pulmonary Manifestations of Sj ögren's Disease
Semin Respir Crit Care Med DOI: 10.1055/s-0044-1785675Sjögren's disease (SjD) is a chronic, progressive autoimmune condition of exocrine and extraglandular tissues. It can present with isolated disease characterized by lymphocytic infiltration of salivary or lacrimal glands, but in approximately one-third of the patients, lymphocytic infiltration extends beyond exocrine glands to involve extraglandular organs such as the lungs. Pulmonary complications have been reported to occur between 9 and 27% of patients with SjD across studies. Respiratory manifestations occur on a spectrum of severity and include airways disease, in...
Source: Seminars in Respiratory and Critical Care Medicine - April 15, 2024 Category: Respiratory Medicine Authors: Byrne, Louise McCarthy, Cormac Fabre, Aurelie Gupta, Nishant Tags: Review Article Source Type: research
